Editas Medicine, Inc. (0IFK.L)
USD 1.46
(-4.63%)
USD 1.46
(-4.63%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 36.53 Million USD | -16.86% |
| 2022 | 43.94 Million USD | 66.6% |
| 2021 | 26.37 Million USD | 0.93% |
| 2020 | 26.13 Million USD | -10.13% |
| 2019 | 29.08 Million USD | -10.29% |
| 2018 | 32.41 Million USD | -3.03% |
| 2017 | 33.43 Million USD | -4.74% |
| 2016 | 35.09 Million USD | -82.44% |
| 2015 | 199.91 Million USD | 48541.12% |
| 2014 | 411 Thousand USD | -80.53% |
| 2013 | 2.11 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 38.69 Million USD | 13.35% |
| 2024 Q1 | 34.13 Million USD | -6.56% |
| 2024 Q3 | 38.48 Million USD | -0.54% |
| 2023 Q2 | 37.18 Million USD | 0.13% |
| 2023 Q3 | 34.61 Million USD | -6.92% |
| 2023 Q4 | 36.53 Million USD | 5.56% |
| 2023 FY | 36.53 Million USD | -16.86% |
| 2023 Q1 | 37.13 Million USD | -15.49% |
| 2022 FY | 43.94 Million USD | 66.6% |
| 2022 Q4 | 43.94 Million USD | 106.31% |
| 2022 Q3 | 21.3 Million USD | 5.15% |
| 2022 Q2 | 20.25 Million USD | -12.55% |
| 2022 Q1 | 23.16 Million USD | -12.19% |
| 2021 Q2 | 30.25 Million USD | 4.75% |
| 2021 Q1 | 28.88 Million USD | 10.52% |
| 2021 Q3 | 28.69 Million USD | -5.17% |
| 2021 Q4 | 26.37 Million USD | -8.07% |
| 2021 FY | 26.37 Million USD | 0.93% |
| 2020 Q1 | 27.17 Million USD | -6.54% |
| 2020 Q2 | 28.8 Million USD | 5.98% |
| 2020 Q3 | 26.71 Million USD | -7.27% |
| 2020 FY | 26.13 Million USD | -10.13% |
| 2020 Q4 | 26.13 Million USD | -2.15% |
| 2019 FY | 29.08 Million USD | -10.29% |
| 2019 Q3 | 17.65 Million USD | 1.25% |
| 2019 Q2 | 17.43 Million USD | -5.15% |
| 2019 Q1 | 18.37 Million USD | -43.31% |
| 2019 Q4 | 29.08 Million USD | 64.76% |
| 2018 Q2 | 32.94 Million USD | -0.74% |
| 2018 Q3 | 32.69 Million USD | -0.76% |
| 2018 FY | 32.41 Million USD | -3.03% |
| 2018 Q4 | 32.41 Million USD | -0.85% |
| 2018 Q1 | 33.19 Million USD | -0.72% |
| 2017 Q3 | 33.66 Million USD | -31.12% |
| 2017 FY | 33.43 Million USD | -4.74% |
| 2017 Q1 | 48.92 Million USD | 39.41% |
| 2017 Q2 | 48.87 Million USD | -0.1% |
| 2017 Q4 | 33.43 Million USD | -0.7% |
| 2016 Q3 | 32.04 Million USD | 41.33% |
| 2016 Q4 | 35.09 Million USD | 9.51% |
| 2016 Q2 | 22.67 Million USD | 94.66% |
| 2016 Q1 | 11.64 Million USD | -94.17% |
| 2016 FY | 35.09 Million USD | -82.44% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 199.91 Million USD | 48541.12% |
| 2015 Q4 | 199.91 Million USD | 10848.25% |
| 2015 Q3 | 1.82 Million USD | 56.07% |
| 2015 Q2 | 1.17 Million USD | 0.0% |
| 2014 Q4 | 411 Thousand USD | 0.0% |
| 2014 FY | 411 Thousand USD | -80.53% |
| 2013 FY | 2.11 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dynavax Technologies Corporation | 256.91 Million USD | 85.779% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 12.019% |
| Perrigo Company plc | 4.07 Billion USD | 99.103% |
| Illumina, Inc. | 2.26 Billion USD | 98.385% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.895% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -3553.6% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.618% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.743% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 78.972% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.648% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -35.369% |
| Waters Corporation | 2.35 Billion USD | 98.449% |
| Biogen Inc. | 7.33 Billion USD | 99.502% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 4.115% |
| Evolus, Inc. | 126.54 Million USD | 71.128% |
| Adicet Bio, Inc. | 17.7 Million USD | -106.383% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 15.361% |
| bluebird bio, Inc. | 330.32 Million USD | 88.939% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 93.246% |
| FibroGen, Inc. | 170.45 Million USD | 78.566% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.664% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -74.945% |
| Homology Medicines, Inc. | 44.05 Million USD | 17.065% |
| Geron Corporation | 85.89 Million USD | 57.466% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 98.476% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 91.791% |
| Myriad Genetics, Inc. | 145 Million USD | 74.803% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -2799.683% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 68.325% |
| Zoetis Inc. | 6.8 Billion USD | 99.463% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -729.986% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 98.315% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 96.778% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 95.48% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -0.586% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 97.486% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 36.868% |
| Verastem, Inc. | 41.55 Million USD | 12.082% |
| Nektar Therapeutics | 230.4 Million USD | 84.142% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 80.396% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1088.549% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 97.384% |
| OPKO Health, Inc. | 326.56 Million USD | 88.812% |
| Exelixis, Inc. | 189.94 Million USD | 80.765% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 91.472% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -24096.026% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 73.603% |
| Imunon, Inc. | 1.13 Million USD | -3106.901% |
| Blueprint Medicines Corporation | 774.12 Million USD | 95.28% |
| Insmed Incorporated | 1.2 Billion USD | 96.965% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.563% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 35.888% |
| TG Therapeutics, Inc. | 110.79 Million USD | 67.024% |
| Incyte Corporation | 38.28 Million USD | 4.573% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 95.836% |